the gaap to non-gaap reconciliation presents non-gaap financial measures that exclude the impact of charges or gains that contribute to or reduce earnings and that may affect financial trends , but which include charges or benefits that result from transactions or events that management believes may or may not recur with similar materiality or impact to our operations in future periods ( non-gaap adjustments ) . in the event there is a non-gaap adjustment recognized in our operating results , the tax cost or benefit attributable to that item is separately calculated . because the effective rate may be significantly affected by the non-gaap adjustments that take place during the period , we often refer to our tax rate using both the effective rate and the non-gaap nominal tax rate ( non-gaap nominal tax rate ) . the non-gaap nominal tax rate is calculated as the provision for income taxes , adjusted for the impact of non-gaap adjustments , as a percentage of income from operations before income taxes , excluding non-gaap adjustments . 39 free cash flow is a non-gaap financial measure calculated by subtracting additions to property , plant , and equipment from net cash provided by operating activities . refer to the “ gaap to non-gaap reconciliation , `` `` income taxes , `` and `` summary of cash flows `` sections for reconciliations of our results of operations prepared in accordance with u.s. gaap to the adjusted non-gaap financial measures considered by management . executive level overview medtronic is among the world 's largest medical technology , services , and solutions companies - alleviating pain , restoring health , and extending life for millions of people around the world . we employ more than 91,000 full-time employees worldwide , serving physicians , hospitals , and patients in approximately 160 countries . our primary products include those for cardiac rhythm disorders , cardiovascular disease , advanced and general surgical care , respiratory and monitoring solutions , neurological disorders , spinal conditions and musculoskeletal trauma , urological and digestive disorders , and ear , nose , and throat and diabetes conditions . net income attributable to medtronic for fiscal year 2017 was $ 4.0 billion , $ 2.89 per diluted share , as compared to net income attributable to medtronic of $ 3.5 billion , $ 2.48 per diluted share , for fiscal year 2016 , representing an increase of 14 percent and 17 percent , respectively . the table below illustrates net sales by operating segment for fiscal years 2017 , 2016 , and 2015 : replace_table_token_6_th ( 1 ) the minimally invasive therapies group was a new group in the fourth quarter of fiscal year 2015 that contains the majority of covidien 's former operations . revenue growth is compared to a full year of operations in fiscal year 2016. currency translation had an unfavorable impact of $ 34 million on net sales for fiscal year 2017 , as compared to fiscal year 2016 when using the average exchange rates in effect during fiscal year 2016 . net sales growth for fiscal year 2017 was also unfavorably affected by an additional selling week during the first quarter of fiscal year 2016 , resulting from our 52/53 week fiscal year calendar . in addition , the fiscal year 2017 acquisitions of heartware and smith & nephew 's gynecology business contributed $ 200 million to our total net sales growth . our performance continues to be fueled by our three growth strategies : therapy innovation , globalization , and economic value . we are creating competitive advantages and capitalizing on the long-term trends in healthcare : namely , the desire to improve clinical outcomes ; the growing demand for expanded access to care ; and the optimization of cost and efficiency within healthcare systems . in our therapy innovation growth strategy , we continue to see strong adoption of our products across all our operating segments . further discussion about our products is included within the operating segment sections below . in globalization , net sales in emerging markets and non-u.s. developed markets grew 7 percent and 4 percent , respectively , in fiscal year 2017 compared to fiscal year 2016 . in our third growth strategy , economic value , we continue to execute our value-based healthcare signature programs and remain focused on leading the shift to healthcare payment systems that reward value and improved patient outcomes over volume . see our discussion in the “ net sales ” section of this management 's discussion and analysis for more information on the results of our operating segments . gaap to non-gaap reconciliation we have provided non-gaap financial measures , because we believe they provide meaningful information regarding our results on a consistent and comparable basis for the periods presented . management uses these non-gaap financial measures to facilitate its review of our operational performance and as a basis for strategic planning . management believes that non-gaap financial measures provide useful information to investors regarding the underlying business trends and performance of our ongoing operations and are useful for period over period comparisons of such operations . refer to our discussion in the `` costs and expenses `` and `` income taxes `` sections of this management 's discussion and analysis for more information on the non-gaap adjustments . investors should not consider results reflecting non-gaap financial measures in isolation from , or as a substitute for , financial information prepared in accordance with u.s. gaap , and should be cautioned that we may calculate results reflecting non-gaap financial measures in a manner that is different from other companies . 40 replace_table_token_7_th ( 1 ) the tax effect of each non-gaap adjustment is based on the jurisdictions in which the expense ( income ) is incurred and the tax laws in effect for each such jurisdiction . story_separator_special_tag coronary & structural heart net sales for fiscal year 2016 were $ 3.1 billion , an increase of 2 percent compared to fiscal year 2015. net sales were driven by the corevalve evolut r recapturable system in the u.s. , which was launched late in the first quarter of fiscal year 2016 , and a strong corevalve launch in japan in the fourth quarter of fiscal year 2016. in addition , net sales of coronary & structural heart division were driven by drug-eluting stents , including the resolute onyx drug-eluting stent in europe and the resolute integrity drug-eluting stent in the u.s. , and the recent launches of the nc euphora and sc euphora balloon dilatation catheters . net sales were partially offset by continued pricing pressures in our coronary business . aortic & peripheral vascular net sales for fiscal year 2016 were $ 1.6 billion , an increase of 52 percent compared to fiscal year 2015. the aortic & peripheral vascular division net sales performance benefited from the addition of the covidien peripheral business in the fourth quarter of fiscal year 2015. the increase in aortic & peripheral vascular net sales was driven by strong growth of the in.pact admiral drug-coated balloon in the u.s. and globally , continued strength in valiant captiva taa stent graft sales , continued solid adoption of our aptus heli-fx endoanchor , and continued adoption of the endurant iis abdominal aortic aneurysm ( aaa ) 3-piece system in the u.s. net sales for the aortic & peripheral vascular division were affected by increased competition in international markets and reimbursement cuts in japan . looking ahead , we expect our cardiac and vascular group could be affected by the following : changes in procedural volumes , competitive and pricing pressure , geographic macro-economic risks , reimbursement challenges , impacts from changes in the mix of our product offerings , the timing of product registration approvals , replacement cycle challenges , and fluctuations in currency exchange rates . integration of our acquisition of heartware , a leading innovator of the heartware ventricular assist system ( hvad system ) , to treat patients around the world suffering from advanced heart failure . the acquisition of heartware in august 2016 broadened the medtronic portfolio of therapies , diagnostic tools and services for patients suffering from heart failure and is part of our therapy innovation strategy to surround the physician with innovative products while focusing on patients and disease states . acceptance and future growth of the crt-p quadripolar pacing system , which received ce mark approval in february 2017 and launched in europe during the fourth quarter of fiscal year 2017. in the u.s. , we received fda approval in may 2017 , and launched in the first quarter of fiscal year 2018. acceptance and future growth of the claria mri crt-d system with effectivcrt diagnostic and effective crt during af algorithm , which launched in the u.s. late in the third quarter of fiscal year 2017 and is expected to launch in japan in fiscal year 2018 . 45 continued future growth from the reveal linq insertable cardiac monitor , which launched in japan in the second quarter of fiscal year 2017. continued future growth of our micra transcatheter pacing system , which we started shipping and physician training in the u.s. in the first quarter of fiscal year 2017. micra is a miniaturized single chamber pacemaker system that is delivered through the femoral vein and is implanted in the right ventricle of the heart . the system does not use a lead and does not have a subcutaneous device pocket underneath the skin as with conventional pacemaker systems . during the fourth quarter of fiscal year 2017 , we received final approval for reimbursement in the u.s. from the centers for medicare & medicaid services for this transformative therapy , which we expect will accelerate sales in the u.s. continued acceptance and future growth from care management services as post-acute care services become even more critical in bundled payment models for different interventions or therapies . continued acceptance and future growth from evolut r 34mm transcatheter aortic heart valve , our next-generation recapturable system with differentiated 16 french equivalent delivery system , which was launched in the u.s. in the third quarter of fiscal year 2017. acceptance and future growth from evolut pro transcatheter aortic valve system ( evolut pro ) , which provides control during deployment to assist with accurate positioning with the ability to recapture and reposition the valve . evolut pro received u.s. fda approval and launched in the fourth quarter of fiscal year 2017. evolut pro is expected to receive ce mark approval and launch in europe late summer 2017. acceptance and future growth from the market release of resolute onyx , which received u.s. fda approval early in the first quarter of fiscal year 2018 and is expected to receive approval in japan during the summer of fiscal year 2018. resolute onyx builds on the resolute integrity drug-eluting coronary stent with thinner struts to improve deliverability and is the first stent to feature our corewire technology , allowing greater visibility during procedures . continued acceptance and future growth of the in.pact admiral drug-coated balloon , including the longer length 150mm sizes , for the treatment of peripheral artery disease in the upper leg . continued acceptance and future growth from the hawkone 6 french ( 6f ) for treating patients with peripheral artery disease ( pad ) , which launched in the u.s. in the third quarter of fiscal year 2017. the hawkone system is designed to remove plaque from the vessel wall and restore blood flow . the new hawkone 6f provides an effective and easy-to-use treatment option for patients with pad both above and below the knee with a single device at a lower profile . minimally invasive therapies group the minimally invasive therapies group 's products span the entire continuum of care with a focus on diseases of

debt and capital our capital structure consists of equity and interest-bearing debt . we use a combination of bank borrowings and commercial paper issuances to fund our short-term financing needs . current debt , including the current portion of our long-term debt and capital lease obligations , at april 28 , 2017 was $ 7.5 billion compared to $ 993 million at april 29 , 2016 . we utilize senior notes to meet our long-term financing needs . long-term debt at april 28 , 2017 was $ 25.9 billion compared to $ 30.1 billion at april 29 , 2016 . total debt at april 28 , 2017 was $ 33.4 billion , compared to $ 31.1 billion at april 29 , 2016 . the increase in total debt was primarily driven by the issuance of three tranches of the 2017 senior notes with an aggregate face value of $ 2.0 billion in march 2017. we will use these funds for general corporate purposes . we maintain a commercial paper program for short-term financing , which allows us to issue unsecured commercial paper notes on a private placement basis up to a maximum aggregate amount outstanding at any time of $ 3.5 billion . at april 28 , 2017 , we had $ 901 million of commercial paper outstanding . no amount of commercial paper was outstanding under this program at april 29 , 2016 .


 Write a concise suspicious activity report of the following text delimited by triple backquotes. Return your response as a formal report which covers the key points highlighting the location,dates,entity names and account holder information in chronological order of the text.
     ```debt and capital our capital structure consists of equity and interest-bearing debt . we use a combination of bank borrowings and commercial paper issuances to fund our short-term financing needs . current debt , including the current portion of our long-term debt and capital lease obligations , at april 28 , 2017 was $ 7.5 billion compared to $ 993 million at april 29 , 2016 . we utilize senior notes to meet our long-term financing needs . long-term debt at april 28 , 2017 was $ 25.9 billion compared to $ 30.1 billion at april 29 , 2016 . total debt at april 28 , 2017 was $ 33.4 billion , compared to $ 31.1 billion at april 29 , 2016 . the increase in total debt was primarily driven by the issuance of three tranches of the 2017 senior notes with an aggregate face value of $ 2.0 billion in march 2017. we will use these funds for general corporate purposes . we maintain a commercial paper program for short-term financing , which allows us to issue unsecured commercial paper notes on a private placement basis up to a maximum aggregate amount outstanding at any time of $ 3.5 billion . at april 28 , 2017 , we had $ 901 million of commercial paper outstanding . no amount of commercial paper was outstanding under this program at april 29 , 2016 .
```    
 Suspicious Activity Report : the gaap to non-gaap reconciliation presents non-gaap financial measures that exclude the impact of charges or gains that contribute to or reduce earnings and that may affect financial trends , but which include charges or benefits that result from transactions or events that management believes may or may not recur with similar materiality or impact to our operations in future periods ( non-gaap adjustments ) . in the event there is a non-gaap adjustment recognized in our operating results , the tax cost or benefit attributable to that item is separately calculated . because the effective rate may be significantly affected by the non-gaap adjustments that take place during the period , we often refer to our tax rate using both the effective rate and the non-gaap nominal tax rate ( non-gaap nominal tax rate ) . the non-gaap nominal tax rate is calculated as the provision for income taxes , adjusted for the impact of non-gaap adjustments , as a percentage of income from operations before income taxes , excluding non-gaap adjustments . 39 free cash flow is a non-gaap financial measure calculated by subtracting additions to property , plant , and equipment from net cash provided by operating activities . refer to the “ gaap to non-gaap reconciliation , `` `` income taxes , `` and `` summary of cash flows `` sections for reconciliations of our results of operations prepared in accordance with u.s. gaap to the adjusted non-gaap financial measures considered by management . executive level overview medtronic is among the world 's largest medical technology , services , and solutions companies - alleviating pain , restoring health , and extending life for millions of people around the world . we employ more than 91,000 full-time employees worldwide , serving physicians , hospitals , and patients in approximately 160 countries . our primary products include those for cardiac rhythm disorders , cardiovascular disease , advanced and general surgical care , respiratory and monitoring solutions , neurological disorders , spinal conditions and musculoskeletal trauma , urological and digestive disorders , and ear , nose , and throat and diabetes conditions . net income attributable to medtronic for fiscal year 2017 was $ 4.0 billion , $ 2.89 per diluted share , as compared to net income attributable to medtronic of $ 3.5 billion , $ 2.48 per diluted share , for fiscal year 2016 , representing an increase of 14 percent and 17 percent , respectively . the table below illustrates net sales by operating segment for fiscal years 2017 , 2016 , and 2015 : replace_table_token_6_th ( 1 ) the minimally invasive therapies group was a new group in the fourth quarter of fiscal year 2015 that contains the majority of covidien 's former operations . revenue growth is compared to a full year of operations in fiscal year 2016. currency translation had an unfavorable impact of $ 34 million on net sales for fiscal year 2017 , as compared to fiscal year 2016 when using the average exchange rates in effect during fiscal year 2016 . net sales growth for fiscal year 2017 was also unfavorably affected by an additional selling week during the first quarter of fiscal year 2016 , resulting from our 52/53 week fiscal year calendar . in addition , the fiscal year 2017 acquisitions of heartware and smith & nephew 's gynecology business contributed $ 200 million to our total net sales growth . our performance continues to be fueled by our three growth strategies : therapy innovation , globalization , and economic value . we are creating competitive advantages and capitalizing on the long-term trends in healthcare : namely , the desire to improve clinical outcomes ; the growing demand for expanded access to care ; and the optimization of cost and efficiency within healthcare systems . in our therapy innovation growth strategy , we continue to see strong adoption of our products across all our operating segments . further discussion about our products is included within the operating segment sections below . in globalization , net sales in emerging markets and non-u.s. developed markets grew 7 percent and 4 percent , respectively , in fiscal year 2017 compared to fiscal year 2016 . in our third growth strategy , economic value , we continue to execute our value-based healthcare signature programs and remain focused on leading the shift to healthcare payment systems that reward value and improved patient outcomes over volume . see our discussion in the “ net sales ” section of this management 's discussion and analysis for more information on the results of our operating segments . gaap to non-gaap reconciliation we have provided non-gaap financial measures , because we believe they provide meaningful information regarding our results on a consistent and comparable basis for the periods presented . management uses these non-gaap financial measures to facilitate its review of our operational performance and as a basis for strategic planning . management believes that non-gaap financial measures provide useful information to investors regarding the underlying business trends and performance of our ongoing operations and are useful for period over period comparisons of such operations . refer to our discussion in the `` costs and expenses `` and `` income taxes `` sections of this management 's discussion and analysis for more information on the non-gaap adjustments . investors should not consider results reflecting non-gaap financial measures in isolation from , or as a substitute for , financial information prepared in accordance with u.s. gaap , and should be cautioned that we may calculate results reflecting non-gaap financial measures in a manner that is different from other companies . 40 replace_table_token_7_th ( 1 ) the tax effect of each non-gaap adjustment is based on the jurisdictions in which the expense ( income ) is incurred and the tax laws in effect for each such jurisdiction . story_separator_special_tag coronary & structural heart net sales for fiscal year 2016 were $ 3.1 billion , an increase of 2 percent compared to fiscal year 2015. net sales were driven by the corevalve evolut r recapturable system in the u.s. , which was launched late in the first quarter of fiscal year 2016 , and a strong corevalve launch in japan in the fourth quarter of fiscal year 2016. in addition , net sales of coronary & structural heart division were driven by drug-eluting stents , including the resolute onyx drug-eluting stent in europe and the resolute integrity drug-eluting stent in the u.s. , and the recent launches of the nc euphora and sc euphora balloon dilatation catheters . net sales were partially offset by continued pricing pressures in our coronary business . aortic & peripheral vascular net sales for fiscal year 2016 were $ 1.6 billion , an increase of 52 percent compared to fiscal year 2015. the aortic & peripheral vascular division net sales performance benefited from the addition of the covidien peripheral business in the fourth quarter of fiscal year 2015. the increase in aortic & peripheral vascular net sales was driven by strong growth of the in.pact admiral drug-coated balloon in the u.s. and globally , continued strength in valiant captiva taa stent graft sales , continued solid adoption of our aptus heli-fx endoanchor , and continued adoption of the endurant iis abdominal aortic aneurysm ( aaa ) 3-piece system in the u.s. net sales for the aortic & peripheral vascular division were affected by increased competition in international markets and reimbursement cuts in japan . looking ahead , we expect our cardiac and vascular group could be affected by the following : changes in procedural volumes , competitive and pricing pressure , geographic macro-economic risks , reimbursement challenges , impacts from changes in the mix of our product offerings , the timing of product registration approvals , replacement cycle challenges , and fluctuations in currency exchange rates . integration of our acquisition of heartware , a leading innovator of the heartware ventricular assist system ( hvad system ) , to treat patients around the world suffering from advanced heart failure . the acquisition of heartware in august 2016 broadened the medtronic portfolio of therapies , diagnostic tools and services for patients suffering from heart failure and is part of our therapy innovation strategy to surround the physician with innovative products while focusing on patients and disease states . acceptance and future growth of the crt-p quadripolar pacing system , which received ce mark approval in february 2017 and launched in europe during the fourth quarter of fiscal year 2017. in the u.s. , we received fda approval in may 2017 , and launched in the first quarter of fiscal year 2018. acceptance and future growth of the claria mri crt-d system with effectivcrt diagnostic and effective crt during af algorithm , which launched in the u.s. late in the third quarter of fiscal year 2017 and is expected to launch in japan in fiscal year 2018 . 45 continued future growth from the reveal linq insertable cardiac monitor , which launched in japan in the second quarter of fiscal year 2017. continued future growth of our micra transcatheter pacing system , which we started shipping and physician training in the u.s. in the first quarter of fiscal year 2017. micra is a miniaturized single chamber pacemaker system that is delivered through the femoral vein and is implanted in the right ventricle of the heart . the system does not use a lead and does not have a subcutaneous device pocket underneath the skin as with conventional pacemaker systems . during the fourth quarter of fiscal year 2017 , we received final approval for reimbursement in the u.s. from the centers for medicare & medicaid services for this transformative therapy , which we expect will accelerate sales in the u.s. continued acceptance and future growth from care management services as post-acute care services become even more critical in bundled payment models for different interventions or therapies . continued acceptance and future growth from evolut r 34mm transcatheter aortic heart valve , our next-generation recapturable system with differentiated 16 french equivalent delivery system , which was launched in the u.s. in the third quarter of fiscal year 2017. acceptance and future growth from evolut pro transcatheter aortic valve system ( evolut pro ) , which provides control during deployment to assist with accurate positioning with the ability to recapture and reposition the valve . evolut pro received u.s. fda approval and launched in the fourth quarter of fiscal year 2017. evolut pro is expected to receive ce mark approval and launch in europe late summer 2017. acceptance and future growth from the market release of resolute onyx , which received u.s. fda approval early in the first quarter of fiscal year 2018 and is expected to receive approval in japan during the summer of fiscal year 2018. resolute onyx builds on the resolute integrity drug-eluting coronary stent with thinner struts to improve deliverability and is the first stent to feature our corewire technology , allowing greater visibility during procedures . continued acceptance and future growth of the in.pact admiral drug-coated balloon , including the longer length 150mm sizes , for the treatment of peripheral artery disease in the upper leg . continued acceptance and future growth from the hawkone 6 french ( 6f ) for treating patients with peripheral artery disease ( pad ) , which launched in the u.s. in the third quarter of fiscal year 2017. the hawkone system is designed to remove plaque from the vessel wall and restore blood flow . the new hawkone 6f provides an effective and easy-to-use treatment option for patients with pad both above and below the knee with a single device at a lower profile . minimally invasive therapies group the minimally invasive therapies group 's products span the entire continuum of care with a focus on diseases of

